anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although the recombinant zoster vaccine (RZV) has demonstrated efficacy in reducing the risk of herpes zoster (HZ) for individuals aged 50 years and older, its effectiveness in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. This study was conducted to assess the effect of RZV on the risk of HZ in COPD patients. A multi-institutional propensity score-matched retrospective cohort study was conducted using the TriNetX Research network, including individuals aged 40 years or older with COPD from January 1, 2018, to December 31, 2022. Patients with a history of HZ or prior zoster vaccination were excluded. The primary outcome was HZ occurrence, with secondary outcomes including severe and nonsevere HZ. After propensity score matching, each 17 431 patients receiving RZV and unvaccinated patients were included. The vaccinated group had a significantly lower risk of HZ compared to the unvaccinated group (HR, 0.62; [95% confidence intervals] 95% CI, 0.51-0.75, p < 0.01). Similar risk reductions were observed for nonsevere HZ (HR, 0.61; 95% CI, 049-0.75, p < 0.01) and severe HZ (HR, 0.53; 95% CI, 0.38-0.73, p < 0.01). Further subgroup analyses demonstrated consistent risk reductions across age (50-59, 60-69, 70-79, and ≥80 years), sex, and comorbidities, except for individual aged 40-49 years. This study confirms the effectiveness of RZV in reducing HZ risk in patients with COPD aged 50 years and older, supporting its administration in this population. However, vaccination rates remain low, highlighting the need for improved vaccination strategies in this high-risk group. Efforts to enhance vaccine uptake are warranted to reduce HZ morbidity.
PURPOSE:To obtain a monoclonal antibody which reacts specifically with a B type antigen only, by a method wherein a splenic cell is sampled from an animal immunized by a human B type red blood cell to form a fused cell between the splenic cell and a myeloma cell and then, a cell stock is cultured to produce an anti-B monoclonal antibody therefrom. CONSTITUTION:A mouse which is found to contain no B antigen or a very few if any by a agglutination blocking test using saliva or an absorption test using red blood cell is used and it is immunized with a 10% human red blood cell solution at a rate of 0.5ml per dose four times at intervals of 3 days by an abnominal injection. The spleen of the mouse is extracted to sample a cell on the 4th day from the final immunization. A stainless mesh is used for the sampling of the cell. NS-1 is used as mouse myeloma cell to be mixed with the splenic cell and the supernatant is removed by a centrifugal separation. Then, BEG and RPM-1640 as medium is applied to the mixed cell mass to form a fused cell, which is caltured on a HAT medium to produce an anti-B monoclonal antibody.
<P>PROBLEM TO BE SOLVED: To obtain a hepatitis C virus production inhibitor, a medicine and a food and beverage using the same.  <P>SOLUTION: The processed product of a blueberry leaf is wholly different from blueberry fruit and has specific inhibitory action on hepatitis C virus production. The processed product of a blueberry may be a leaf itself and is preferably selected from dried ground blueberry, squeezed blueberry juice and an extract of blueberry properly depending upon uses. Water, an aqueous solution of alcohol or an alcohol is preferably used as the most usable extractive solvent of extract. An aqueous solution of ethanol is optimally used from the viewpoint of safety. A hepatitis C virus production inhibitor and a hepatitis therapeutic agent effectively useful for preventing chronic hepatitis, cirrhosis hepatis development and preventing hepatoma development or a functional food and beverage for ameliorating them may be cited as the main uses of the medicine.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The infants will be recruited and randomized between 0 and 14 days. The intervention period, in terms of data necessary for the primary outcome, will be until they reach 3 months old. Measurements will be collected on three separate occasions during this period, i.e. 2 and 6 weeks and 3 months. Stools will be collected, on 3 separate occasions, i.e. 4-5 day, 6 weeks and 3 months of life.
Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
Malnutrition in early life increases the risk of osteoporosis, but the association of early-life undernutrition combined with adulthood obesity patterns with low-energy fracture remains unknown. This study included 5323 community-dwelling subjects aged ⩾40 years from China. Early-life famine exposure was identified based on the participants' birth dates. General obesity was assessed using the body mass index (BMI), and abdominal obesity was evaluated with the waist-to-hip ratio (WHR). Low-energy fracture was defined as fracture occurring after the age of ⩾40 typically caused by falls from standing height or lower. Compared to the nonexposed group, the group with fetal, childhood, and adolescence famine exposure was associated with an increased risk of fracture in women with odds ratios (ORs) and 95% confidence intervals (CIs) of 3.55 (1.57-8.05), 3.90 (1.57-9.71), and 3.53 (1.05-11.88), respectively, but not in men. Significant interactions were observed between fetal famine exposure and general obesity with fracture among women (P for interaction = 0.0008). Furthermore, compared with the groups with normal BMI and WHR, the group of women who underwent fetal famine exposure and had both general and abdominal obesity had the highest risk of fracture (OR, 95% CI: 3.32, 1.17-9.40). These results indicate that early-life famine exposure interacts with adulthood general obesity and significantly increases the risk of low-energy fracture later in life in women.
A networked health care and monitoring system (10) capable of providing an updated reliable vital information on the health condition of individuals includes measuring devices (39) associated with a household appliance such as a toilet system (12,31) and adapted to monitor the vital information passively in response to the use thereof in connection with routine living activities of the individuals. The system may further include measuring devices (43;46;49;56) associated with other household appliances, such as an ergometer (15,34), having health care and maintenance functions and adapted to control the appliances based on the vital information monitored by the measuring devices in the system. In one embodiment wherein the system is arranged in the centralized network configuration, the measuring devices are connected via a local area network (LAN) with a data controller (20) wherein all the vital information obtained in the system is stored. The measurement devices (39;43;46;49;56) are permitted to access the controller through the network to retrieve necessary vital information therefrom. In another embodiment arranged in the distributed network configuration, the vital information obtained by respective measuring devices is stored therein and is furnished upon request to the other appliances. <IMAGE>
A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
Disclosed herein is a method for inducing Hsp72 production in a cell. The method involves contacting the cell transiently with a proteasome inhibitor in an amount sufficient to induce Hsp72 production. Preferably Hsp72 levels are induced to a level sufficient for the suppression of stress-activated kinase activity attributable, for example, to a stress-activated kinase selected from the group consisting of JNK and p38. The method has both in vitro and in vivo applications. Also disclosed is a method of the type described above is applied specifically to aged cells. Also disclosed is a method for treating pathologies associated with apoptosis and inflammation in an individual. The method involves administering to the individual a proteasome inhibitor in an amount sufficient to induce Hsp72 production. In a preferred embodiment of the therapeutic method, the individual is an aged individual. Stress-induced pathologies such as ischemia are particularly important with respect to the therapeutic aspect of the invention. Also disclosed is a method for identifying an organic compound having the ability to induce Hsp72 levels in aged cells to a level sufficient to suppress stress-activated kinase activity.
BACKGROUND: Mucosal gastric atrophy and intestinal metaplasia (IM) increase the risk for the development of gastric cancer (GC) as they represent a field for development of dysplasia and intestinal-type gastric adenocarcinoma.
METHODS: We have investigated the expression of two dysplasia markers, CEACAM5 and TROP2, in human antral IM and gastric tumors to assess their potential as molecular markers.
RESULTS: In the normal antral mucosa, weak CEACAM5 and TROP2 expression was only observed in the foveolar epithelium, while inflamed antrum exhibited increased expression of both markers. Complete IM exhibited weak CEACAM5 expression at the apical surface, but no basolateral TROP2 expression. On the other hand, incomplete IM demonstrated high levels of both CEACAM5 and TROP2 expression. Notably, incomplete IM with dysplastic morphology (dysplastic incomplete IM) exhibited higher levels of CEACAM5 and TROP2 expression compared to incomplete IM without dysplastic features (simple incomplete IM). In addition, dysplastic incomplete IM showed diminished SOX2 and elevated CDX2 expression compared to simple incomplete IM. CEACAM5 and TROP2 positivity in incomplete IM was similar to that of gastric adenomas and GC. Significant association was found between CEACAM5 and TROP2 positivity and histology of GC.
CONCLUSIONS: These findings support the concept that incomplete IM is more likely associated with GC development. Overall, our study provides evidence of the heterogeneity of gastric IM and the distinct expression profiles of CEACAM5 and TROP2 in dysplastic incomplete IM. Our findings support the potential use of CEACAM5 and TROP2 as molecular markers for identifying individuals with a higher risk of GC development in the context of incomplete IM.
ABSTRACT OF THE DISCLOSURE    A novel pharmaceutical composition is provided herein for mediating    the    physiological    effects of    hormones, neurotransmitters,  calcium-channel antagonists or chemotactic peptides.   The novel pharmaceutical composition comprises a compound selected from the group consisting of peptide hormones, neurotransmitters,  calcium  channel  antagonists,  chemotactic peptides, and their agonists, antagonists and analogues, a source of Ca2+ and/or Mg2+ ions, and a solvent selected from the group consisting of alcohols, ketones, ethers and lipids. The compound binds to the Ca2+ and/or Mg2+_ ion and,  as a result of such binding,  assumes a bioactive, amphilic conformation which is different from the conformation of the compound in the solvent prior to binding.  The biactive amphilic conformation is one in which the Ca2+ and/or Mg2+ ions are so bound to the compound as to provide a unique, 3-dimensional structure of a molecule.  By the present invention, the concentration of intracellular Ca2+ is raised by means  of such novel compounds.   By the present invention, also, a method is provided for delivering Ca2+ and/or Mg2+ to a membrane-bound receptor by transporting Ca2+ and/or Mg2+ through  a cell  membrane  using  the  above-described  novel pharmaceutical compositions.
FIELD: medicine, chemical-pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to development of effective analgetic, spasmolytic and anti-inflammatory agent. Invention proposes analgetic, spasmolytic, anti-inflammatory agent characterized by that it presents pharmaceutical composition comprising spasmolytic component and/or at least one non-narcotic analgetic, alkaloid of purine order, barbiturate as sedative component taken among the group: phenobarbital, pentobarbital, cyclobarbital and at least one compound taken among nonsteroid anti-inflammatory agents: ibuprofen, ortophen, indometacin, piroxicam, ketoprofen, meloxicam, nabumetone and/or its mixture with agonist of opioid receptors. Proposed combined preparation arrests pain of practically any etiology. Preparation shows prolonged analgetic and spasmolytic effect and expressed anti-inflammatory effect. Adverse effects of this preparation, for example, dyspeptic symptoms, vertigo, epigastralgia are less expressed in using this preparation. EFFECT: improved and valuable medicinal properties of agent. 9 cl, 9 ex
Idiopathic central precocious puberty (CPP) is an important treatable disease causing pubertal growth disorders. Gonadotropin-releasing hormone analogs (GnRHa) are the first-line drugs for treating idiopathic central precocious puberty (ICPP). Currently, the 1-month formulation (3.75mg) is the most widely used in China. The development of long-acting formulations will reduce the number of injections and treatment costs for children, as well as reduce the clinical visit burden. The 3-month formulation of Triptorelin Pamoate (15mg) was approved for use in central precocious puberty in March 2023. At present, there is only one publicly reported small-sample, single-arm clinical study in China, and there are no large-sample, real-world, concurrent controlled clinical study data on the efficacy and safety of the 3-month and 1-month formulations of triptorelin in the treatment of central precocious puberty. In currently reported safety events both domestically and internationally, there are no reports on the effects of the 3-month formulation of triptorelin on patients' glucose and lipid metabolism, body composition, and bone density. Our research team previously observed in a small-sample retrospective study of female patients with ICPP that after 1 year of treatment with the 3-month formulation of GnRHa (11.25mg leuprorelin), it effectively inhibited the hypothalamic-pituitary-gonadal axis and bone age progression, improved predicted adult height, and had no serious safety events. Therefore, based on our previous work, we plan to conduct a large-sample, real-world, concurrent controlled study to evaluate the gonadal axis suppression and predicted adult height benefits of the 3-month formulation of triptorelin compared to the 1-month formulation in patients with central precocious puberty (CPP). Additionally, we will assess the short-term effects of the 3-month formulation of triptorelin on glucose and lipid metabolism, body composition, and bone density in ICPP patients. The study results are expected to provide clinical evidence for the application of the 3-month formulation in the treatment of central precocious puberty in China.
Treatment with appropriate antibiotics does not seem to be associated with prognosis among elderly patients with pneumonia. Identifying factors associated with poor prognosis despite the use of appropriate antibiotics might help withhold aggressive antibiotic treatment in patients with pneumonia. This systematic review aims to identify the risk factors associated with unfavored outcomes despite using appropriate antibiotics for pneumonia. The PubMed database was searched for studies focusing on appropriate antibiotic use in patients with pneumonia (assessed on Aug 7, 2024). Appropriate antibiotics were defined as those sensitive to microorganisms isolated from patients. The risk of bias was evaluated using the Risk of Bias Assessment tool for nonrandomized Studies utilized for controlled observational studies. A total of 1563 studies were identified from the database, and eight observational studies were included in this review: ventilator-associated pneumonia (n = 4), community-onset pneumonia (n = 2), P. aeruginosa pneumonia (n = 1), and S. maltophilia pneumonia (n = 1). Advanced age was the most commonly evaluated factor associated with mortality. Additionally, high severity scores were related to the unfavored outcomes even after treatment with appropriate antibiotics. Advanced age and high severity scores may be associated with increased mortality despite appropriate antibiotic usage for pneumonia. Broad-spectrum antibiotics might not be indicated in elderly pneumonia patients with high severity status who do not wish to receive aggressive antibiotic treatments.
The evolution of parasite resistance to antiparasitic agents has become a serious health issue indicating a critical and pressing need to develop new therapeutics that can conquer drug resistance. Nanoparticles are novel, promising emerging drug carriers that have demonstrated efficiency in treating many parasitic diseases. Lately, attention has been drawn to a broad-spectrum nanoparticle capable of converting absorbed light into heat via the photothermal effect phenomenon. The present study is the first to assess the effect of silver nanoparticles (Ag NPs) and iron oxide nanoparticles (Fe3O4 NPs) as sole agents and with the combined action of the light-emitting diode (LED) on Blastocystis hominins (B. hominis) in vitro. Initially, the aqueous synthesized nanoparticles were characterized by UV-Vis spectroscopy, zeta potential, and transmission electron microscopy (TEM). The anti-blastocyst efficiency of these NPs was tested separately in dark conditions. As these NPs have a wide absorption spectrum in the visible regions, they were also excited by a continuous wave LED of wavelength band (400-700 nm) to test the photothermal effect. The sensitivity of B. hominis cysts was evaluated using scanning laser confocal microscopy whereas the live and dead cells were accurately segmented based on superpixels and the k-mean clustering algorithm. Our findings showed that this excitation led to hyperthermia that induced a significant reduction in the number of cysts treated with photothermally active NPs. The results of this study elucidate the potential role of photothermally active NPs as an effective anti-blastocystis agent. By using this approach, new therapeutic antiparasitic agents can be developed.
A method of creating a virtual 3D model of a bone is provided. The method involves scanning a bone using an ultrasound transducer while tracking a three dimensional (3D) position of the ultrasound transducer using a 3D position tracker. Ultrasound signals representative of ultrasound echoes detected by the ultrasound transducer are acquired during scanning. Data from the 3D position tracker is acquired and used to determine the 3D position of the ultrasound transducer during scanning. A plurality of virtual 3D bone surface points is generated using the 3D position of the ultrasound transducer during scanning and the acquired ultrasound signals. A  virtual 3D model of the bone is created using the bone surface points to deform a non-patient specific bone model representative of the bone.
The invention provides a recombinant protein AC-01 and a secretion type isomer thereof. The amino acid sequence of the recombinant protein AC-01 is shown by SEQ ID NO:1, and the amino acid sequence of the secretion type isomer is shown by SEQ ID NO:3. The invention also provides a nucleotide sequence for coding the protein and the secretion type isomer thereof, a carrier containing the nucleotide sequence, and a corresponding host cell. The nucleotide sequence is shown by SEQ ID NO:2 and 4 respectively. The protein has a certain correlation with an unfolded protein response and an endoplasmic reticulum stress, and an effect of significantly inhibiting the proliferation of human colon cancer cells SW480. Therefore, the invention also provides a pharmaceutical composition containing the protein or the secretion type isomer thereof, and an application of the pharmaceutical composition containing the protein or the secretion type isomer thereof in treatment and prevention of cancer.
The invention provides a cyclic alkenylimine medical intermediate, a preparation method and an inhibitory activity of the cyclic alkenylimine medical intermediate on the growth of cancer cells. The general formula is as follows In the formula R  1  Is n-butyl, tert-butyl, phenyl, cyclohexyl or benzyl, R  2  Is alkyl such as methyl, ethyl, isopropyl, n-hexyl and the like, aryl such as phenyl, substituted phenyl and the like or heteroaryl. R is  3  Is alkyl such as methyl, ethyl, isopropyl, n-hexyl, etc., aryl such as phenyl, substituted phenyl, etc., or heteroaryl. The position and the number of the substituent groups are not fixed. The preparation method comprises the steps of substituting an alpha-phosphinimine for an acrolein derivative, an acid and an isonitrile, reacting in a solvent of anhydrous 1, 2-dichloroethane, removing the solvent under reduced pressure after the reaction is finished, and carrying out column chromatography on residues to obtain the target compound shown in the general formula (I). The invention provides a novel efficient synthesis method to synthesize a class of cyclic alkenylene imine derivatives, and the derivatives show certain inhibitory activity to human liver cancer cells HepG-2 and lung cancer cells A549-1, thereby being beneficial to being applied as medicines.
PURPOSE: A composition for prevention and treatment of diabetes including a NAD glycohydrolase inhibitor as an active ingredient is provided to be used as a cure for diabetes, especially type 2 diabetes, by accelerating hypoglycemic and insulin secretion. CONSTITUTION: A composition for prevention and treatment of diabetes comprises a development inhibitor or an activity inhibitor of NADase as an active ingredient. A NADase is originated from a mammal. The NADase is encoded as a base sequence of sequence number 1 or 2. Diabetes is type 2 diabetes. The active inhibitor is any one selected from a group comprised of antisense nucleotide, siRNA(short interfering RNA), and shRNA(short hairpin RNA) for complementarily uniting to mRNA of a NADase gene.
Approximately 5% of pregnancies worldwide and in the United States were complicated by preeclampsia. Women who develop Preeclampsia in Pregnancy go on to develop Cardiovascular issues (Catov and other studies). Further, infants from preeclamptic pregnancies are at increased risk of mortality and co-morbid conditions (hypertension, excessive weight gain, increased BMI). However, preliminary data suggests that exercise will attenuate or prevent the severity and risk of preeclampsia; thus improving health for women and children. The purpose of this study is to compare the effects of aerobic (AE), resistance (RE), and combination (AERE) exercise throughout pregnancy on selected maternal and fetal/neonatal physiological variables in women at-risk for preeclampsia. The investigators hypothesize that following changes will occur:(1) improvements in the measurements of maternal resting heart rate, blood pressure, cardiometabolic risk (CMR) score, placental growth factor (PlGF), preeclampsia severity, onset of preeclampsia of symptoms at each time point (once per visit); and (2) improvements in birth and infant measurements of decreased C-sections, preterm deliveries, hospital stay, birth weight, placental efficiency at birth when exposed to different modes of maternal exercise compared no exercise (usual care) with greatest differences in AERE trained group. Ultimately, our goal is to determine which exercise program is most effective at attenuating or preventing preeclampsia and thus improving health outcomes for mother and child.